Continuous Positive Airway Pressure Compliance in Patients with Obstructive Sleep Apnea

Shahla Afsharpaim 1, Ehsan Shahverdi 2, Encieh Vahedi 3, Hossein Aqaee 2

Background: Obstructive sleep apnea (OSA) is a common condition in adults. In most cases, first-line therapy includes treatment with positive airway pressure devices. However, because of discomfort, continuous positive airway pressure (CPAP) compliance is often poor. To determine the willingness of patients to use CPAP device, the relationship of demographic and polysomnographic variables with tolerance and the willingness to use CPAP, was evaluated.

Materials and Methods: In this cross-sectional study, 120 OSA patients who were treated with CPAP in Baqiyatallah Hospital, Tehran, Iran, were selected by convenience sampling. Polysomnographic variables, willingness to use CPAP for short and long periods of time and possible complications were evaluated.

Results: One hundred-twenty cases with a mean age of 53±10.3 years were assessed. The mean Epworth Sleepiness Scale (ESS) score was 11.9 ± 6.2 in CPAP users versus 11.8±6.1 in patients who did not use CPAP. The willingness to use CPAP for short-term was significantly different between the two groups (P=0.008). The average minimum oxygen saturation rate of patients was 75.21% in CPAP users versus 71.63% in non CPAP users. Also, the average desaturation index was higher in CPAP users (54.5 vs. 44.98). The mean ESS was 14.03 ± 6.19 in those who accepted long-term treatment versus 8.85 ± 4.89 (P=0.003). Skin wounds and rhinitis were reported in 4.1% and 4.1% of patients, respectively.

Conclusion: It is concluded that high CPAP compliance rates are achievable through comprehensive CPAP therapy.

Key words: Sleep Apnea, Obstructive; Continuous Positive Airway Pressure; Compliance

INTRODUCTION

Obstructive sleep apnea is a common condition affecting 2% of adult female and 4% of adult male populations (1). Obstructive sleep apnea has been associated with multiple poor outcomes, including impaired quality of life (2), high accident rates (3) and increased cardiovascular morbidity and mortality (4, 5).

Treatment is aimed at decreasing symptoms and cardiovascular morbidity and reducing mortality (5, 6).

In most cases, first-line therapy for OSA includes treatment with positive airway pressure devices (6). This type of treatment is highly effective for controlling OSA and decreasing the related symptoms (6, 7). Moreover, the
use of CPAP can decrease systemic blood pressure and improve cardiovascular function; as the result, cardiovascular morbidity and mortality associated with OSA decrease. However, in those who accept treatment with CPAP compliance is often poor because of discomfort. Poor compliance may lower the efficacy of treatment or even result in treatment failure (8, 9). The nasal mask interface may cause complications such as pressure sores, persistent air leak, claustrophobia and nasal congestion (10).

To determine the willingness of patients to use CPAP device, this study sought to assess the relationship of demographic and polysomnographic variables with tolerance and the willingness to use CPAP.

MATERIALS AND METHODS

In this cross-sectional study, after obtaining the ethics approval and patients’ written informed consent, 120 OSA cases treated with CPAP in Baqiyatallah Hospital in Tehran, Iran in 2014 were selected by convenience sampling. The OSA was diagnosed by a pulmonologist with 10 years of clinical experience. Polysomnographic variables included minimum oxygen saturation and respiratory disturbance index (RDI). Willingness of the patients to use CPAP for a short (one day after polysomnography) and long periods of time (six-12 months after polysomnography) was evaluated. If the patient did not use CPAP device, we asked the reasons. Also, we asked about possible complications such as skin wounds and rhinitis.

The indications for use of CPAP, and a time interval of minimum of six months since recommending CPAP therapy were the inclusion criteria. Patients who had not undergone polysomnographic assessment, those not consenting to participate in the study and patients with a history of stress or anxiety and cardiovascular or neurological diseases were excluded from the study.

The patients received sleep hygiene education and were requested to sign an informed consent form before filling out the questionnaire. The questionnaires were filled out anonymously.

The data were analyzed using SPSS version 16 (SPSS Inc. Chicago, IL, USA). The variables with normal distribution (approved by one-sample Kolmogorov-Smirnov test) were compared using independent sample t-test between the groups and paired sample t-test within the groups. Chi square test was also used to compare categorical variables between the two groups. P value<0.05 was considered statistically significant.

RESULTS

Totally, 120 cases with a mean age of 53±10.3 years were evaluated; 71 patients (59.2%) did not use CPAP device. The maximum and minimum age was 80 and 26 years, respectively.

Eight patients (6.7%) were illiterate and 44 patients (36.7%) had academic education. Total ESS score was 11.87±6.15 with a maximum of 24 and minimum of zero (Table 1).

Of 120 patients, 14 (11.7%), 34 (28.3%) and 72 (60%) patients had mild, moderate and severe obstructive RDI, respectively.

Table 1 shows the willingness of patients to use CPAP for a short period of time based on the use or no-use of the device. The willingness of patients to use CPAP for a short period of time was significantly different between the two groups (P=0.008).

Average minimum oxygen saturation of patients was 75.21 % in CPAP users versus 71.63% in non-users. Also, the average desaturation index in CPAP users was higher (54.5 versus 44.98). The difference in the minimum oxygen saturation and desaturation index was not significant. (P=0.24 and P=0.14, respectively, Table 2).
Of 49 patients who had used CPAP device, 29 patients (59.2%) were willing to use it for long-term. Thus, final compliance rate was estimated to be 59.2%. The rate of compliance was higher in patients with weight loss (20.4%) compared to those without weight loss.

The mean age was 56.37 ± 8.99 years in patients who accepted long-term use of CPAP and 49.1 ± 5.08 years in patients who did not accept the long-term use of CPAP. The difference in the mean age between the two groups was significant (P=0.02).

Of 29 patients who used CPAP for a long period of time, 24 were males. Sex did not significantly affect acceptance of CPAP (P=0.07).

In patients who accepted long-term therapy with CPAP, 34.5% had academic education; this rate was 20% in the other group. Education level did not significantly affect long-term acceptance of CPAP device (P=0.09).

The mean ESS score was 14.03 ± 6.19 in those who accepted long-term treatment and 8.85 ± 4.89 in those who did not accept it. The difference in the mean ESS score between the two groups was significant (P=0.003).

The relationship between RDI and long-term use of CPAP device was not significant (P=0.33). Table 3 shows the correlation between long-term use of CPAP and obstructive RDI.

The mean minimum oxygen saturation in CPAP users and non-users was 67.54 and 75.55, respectively. This difference was not significant (P=0.05).

The mean desaturation Index was 62.22 in CPAP users and 43.20 in non-users. This difference was not significant (P=0.05).

A total of 12.2% of patients were not satisfied with the CPAP device and the most common reason was the high price of the device. Table 4 shows reasons for not using CPAP device by patients.

Of 49 patients who used CPAP device, 59.2%, 28.6%, and 12.2% used the device five to seven, three to five and one to three times a week, respectively.

The CPAP device caused no complication in 81.6% of patients; 10.2% of patients reported skin wounds with rhinitis. Skin wounds were reported by 4.1% and rhinitis was reported by 4.1% of patients.

Of 120 patients, 50 patients (41.7%) had chemical injuries. Among them, 11 patients (9.2%) had mild RDI; 10 patients (8.3%) had moderate and 29 patients (24.2%) had severe RDI. These values for non-chemical injuries were 2.5%, 20%, and 35.8%, respectively. The RDI and chemical injury had a significant correlation (P=0.007).

The mean ESS score was 11.54±5.37 in chemical injuries and 12.11±6.69 in non-chemical injuries. This difference was not statistically significant (P=0.61).

According to Table 5, the mean minimum oxygen saturation rate was 74.22 ± 15.20 in chemical injuries and 73.41 ± 17.40 in non-chemical injuries. The difference in minimum oxygen saturation rate between the two groups was not significant (P=0.79).
DISCUSSION

We found that 40.8% of patients used the device and the compliance rate was 59.2%. In patients who used CPAP, the ESS score was significantly higher compared to non-users (16.5 vs. 11.8, P=0.003). This study showed that the association between apnea-hypopnea index and chemical injury was significant (P=0.007). In fact, this relationship described the severity of symptoms of chemical injuries; also, the ESS score was not significantly higher in patients with chemical injury (P=0.61).

This study showed that weight loss was followed by a feeling of satisfaction. The main causes of dissatisfaction with the device were mask size mismatch, feeling of suffocation and complications such as nasal congestion and irritation. Lasters et al. (11) demonstrated the significant effect of treatment of nasal symptoms on patients' compliance. The main cause of not using CPAP was the high cost of the device.

According to Engleman and Wild (12), about 50% of patients who received CPAP therapy discontinued it within the first year. It was shown that humidification, mask selection, and patient education played important roles in improving compliance (13-16).

Boyaci et al. (17) reported compliance rate of 81.9% in patients with obstructive sleep apnea, which was higher than the rate in our study (59.2%). Due to the differences in the details of the study sample size and the type of device (Smart type), such a difference in the rate of compliance was expected. Also, they concluded that patients with higher ESS had higher tolerance and acceptance of CPAP device, confirming the results of our study.

In the recent study, the relationship between apnea/hypopnea index and the compliance of patients was not significant (p=0.33). This finding was highlighted in some previous studies as well (17-20). According to Hui et al. (21) this association was significant and it was the only predictive factor contributing to better compliance in use of the device (P=0.04).

The difference in minimum oxygen saturation and desaturation index between the two groups was not significant and there was no significant relationship between the level of compliance and these two variables in our study but according to Sarrell et al. (22) this relationship was significant.

According to Boyaci et al. (17) gender significantly affected the admission of patients to use CPAP device. But,
it was not in line with our findings. Considering the low number of female patients in this study and variable gender distribution, this difference can be justified.

Boyaci et al. (17) showed that people with higher educational level had better compliance. We achieved these findings in our study as well.

Hui et al. (21) mentioned the role of treatment cost in the selection process. In our study, cost of treatment was so high that it was the first complaint of patients.

In our study, 18.4% of the users of the device had complications, which was lower than the rate reported by Boyaci (17) (18.4% vs. 62%)

**CONCLUSION**

In conclusion, we can state that high CPAP compliance rates are achievable in the community through a comprehensive CPAP program that provides insurance coverage for CPAP devices, extensive education, and follow-up services for symptomatic OSA patients. Finally, further studies with a larger sample size are suggested to confirm the results of this study.

**Conflict of interest**

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

**REFERENCES**

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993; 328 (17): 1230-5.
2. Finn L, Young T, Palta M, Fryback DG. Sleep-disordered breathing and self-reported general health status in the Wisconsin Sleep Cohort Study. *Sleep* 1998; 21 (7): 701- 6.
3. Vorona RD, Ware JC. Sleep disordered breathing and driving risk. *Curr Opin Pulm Med* 2002; 8 (6): 506- 10.
4. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. *Am J Respir Crit Care Med* 2002; 166 (2): 159- 65.
5. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med* 2005; 353 (19): 2034- 41.
6. Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, et al. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. *Sleep* 2006; 29(3): 375- 80.
7. Patel SR, White DP, Malhotra A, Stanchina ML, Ayas NT. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. *Arch Intern Med* 2003; 163 (5): 565- 71.
8. Lewis KE, Seale L, Bartle IE, Watkins AJ, Ebden P. Early predictors of CPAP use for the treatment of obstructive sleep apnea. *Sleep* 2004; 27(1): 134- 8.
9. Lin HS, Zuliani G, Amjad EH, Prasad AS, Badr MS, Pan CJ, et al. Treatment compliance in patients lost to follow-up after polysomnography. *Otolaryngol Head Neck Surg* 2007; 136 (2): 236- 40.
10. Berry RB. Improving CPAP compliance - man more than machine. *Sleep Med* 2000; 1(3): 175- 8.
11. Lasters F, Mallegho C, Boudewyns A, Vanderveken O, Cox T, Ketelslagers K, et al. Nasal symptoms in patients with obstructive sleep apnea and their impact on therapeutic compliance with continuous positive airway pressure. *Acta Clin Belg* 2014; 69(2): 87-91.
12. Engleman HM, Wild MR. Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS). *Sleep Med Rev* 2003; 7(1): 81-99.
13. Massie CA, Hart RW, Peralez K, Richards GN. Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure. *Chest* 1999; 116(2): 403-8.

14. Massie CA, Hart RW. Clinical outcomes related to interface type in patients with obstructive sleep apnea/hypopnea syndrome who are using continuous positive airway pressure. *Chest* 2003; 123(4): 1112-8.

15. Hoy CJ, Vennelle M, Kingshott RN, Engleman HM, Douglas NJ. Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome? *Am J Respir Crit Care Med* 1999; 159(4 Pt 1): 1096-100.

16. Likar LL, Panciera TM, Erickson AD, Rounds S. Group education sessions and compliance with nasal CPAP therapy. *Chest* 1997; 111(5): 1273-7.

17. Boyacı H, Gacar K, Barış SA, Başyığıt I, Yıldız F. Positive airway pressure device compliance of the patients with obstructive sleep apnea syndrome. *Adv Clin Exp Med* 2013; 22 (6): 809-15.

18. Waldhorn RE, Herrick TW, Nguyen MC, O'Donnell AE, Sodero J, Potolicchio Sj. Long-term compliance with nasal continuous positive airway pressure therapy of obstructive sleep apnea. *Chest* 1990; 97(1): 33-8.

19. Krieger J. Long-term compliance with nasal continuous positive airway pressure (CPAP) in obstructive sleep apnea patients and nonapnic snorers. Sleep: Journal of Sleep Research & Sleep Medicine. 1992.

20. Engleman HM, Martin SE, Douglas NJ. Compliance with CPAP therapy in patients with the sleep apnoea/hypopnoea syndrome. *Thorax* 1994; 49(3): 263-6.

21. Hui DS, Choy DK, Li TS, Ko FW, Wong KK, Chan JK, et al. Determinants of continuous positive airway pressure compliance in a group of Chinese patients with obstructive sleep apnea. *Chest* 2001; 120(1): 170-6.

22. Sarrell EM, Chomsky O, Shechter D. Treatment compliance with continuous positive airway pressure device among adults with obstructive sleep apnea (OSA): how many adhere to treatment?. *Harefuah* 2013; 152(3): 140-4, 184, 183.